MaxCyte, Inc. (MXCT) Stock
Healthcare · Medical Devices · Member of Other US Stocks
MaxCyte, Inc. (MXCT) closed at USD 1.25 on 2026-10-14, a change of -19.4 % over the past year, with a market capitalization of USD 134.17M.
MaxCyte, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 1.25 |
| 2026-10-13 | 0.96 |
| 2026-10-12 | 1.00 |
| 2026-10-09 | 1.01 |
| 2026-10-08 | 1.02 |
| 2026-10-07 | 1.04 |
| 2026-10-06 | 1.09 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
MaxCyte, Inc. key figures
- Previous close
- USD 1.25 (2026-10-14)
- 1-year change
- -19.4 %
- Market cap
- USD 134.17M
- Enterprise value
- USD 45.73M
- P/E ratio (trailing)
- -3.71
- P/E ratio (forward)
- -5.30
- EPS (trailing)
- -0.35
- EPS (forward)
- -0.25
- PEG ratio
- n/a
- Price to book
- 0.87
- Revenue growth
- -14.5 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 2.72
- Employees
- 91
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for MaxCyte, Inc. and compare it with other stocks.
Analyze MXCTAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell MaxCyte, Inc. shares.